Claims for Patent: 11,918,559

Summary for Patent: 11,918,559

Title:	Reduced dose metaxalone formulations
Abstract:	Oral dosage forms of metaxalone having improved bioavailability in the fed and fasted states, including dosage forms that employ a reduced dose based on such improved bioavailability.
Inventor(s):	Mukteeshwar Gande, Robert M. Levy
Assignee:	Primus Pharmceuticals Inc , PRIMUS PHARMACEUTICALS Inc
Application Number:	US18/197,100
Patent Claims:	1. A solid oral pharmaceutical tablet consisting essentially of 640 mg of metaxalone and one or more pharmaceutically acceptable excipients, wherein the metaxalone consists essentially of from 40 to 80 wt % of a first grade of particles of metaxalone and from 20 to 60 wt % of a second grade of particles of metaxalone and 10 to 30 weight parts propylene glycol alginate, further wherein: a) 90% of the first grade of particles of metaxalone are smaller than 100 microns when tested according to the Malvern Method; b) at least 35% of the second grade of particles of metaxalone are retained on a #120 sieve when tested by the Sieve Method; c) the first and second grades of metaxalone cause the oral dosage form to be bioequivalent to itself under both fed and fasted conditions in terms of AUC0-inf, wherein said bioequivalence is the 90% confidence interval for a geometric mean test-to-reference area, and whereby peak concentration ratios are within a bioequivalence interval of 0.80-1.25. 2. The solid oral pharmaceutical tablet of claim 1 wherein: a) 90% if the first grade of particles of metaxalone are smaller than 75 microns when tested according to the Malvern Method; and b) less than 5% of the second grade of particles are retained on a #30 sieve when tested by the Sieve Method. 3. An oral dosage form consisting essentially of micronized metaxalone and non-micronized metaxalone, propylene glycol alginate, and alginic acid. 4. The oral dosage form formulation of claim 3, wherein the oral dosage form is bioequivalent to itself under both fed and fasted conditions in terms of and AUC0-inf, whereby said bioequivalence is the 90% confidence interval for a geometric mean test-to-reference area, and whereby peak concentration ratios are within a bioequivalence interval of 0.80-1.25. 5. The oral dosage form of claim 3, wherein: a) the micronized metaxalone comprises 10% 0.8111 micronized metaxalone, 50% 10.00μ micronized metaxalone, and 90% 49.91μ micronized metaxalone, and, b) the non-micronized metaxalone comprises 1 w/w % retained Sieve #30 non-micronized metaxalone, 49-63 w/w % retained Sieve #120 non-micronized metaxalone, and 28-30% retained Sieve #325 non-micronized metaxalone. 6. The oral dosage form of claim 3, further consisting essentially of: a) 10-30 weight parts propylene glycol alginate, b) 20-35 weight parts lactose monohydrate, c) 10-30 weight parts alginic acid, d) 40-60 weight parts povidone, and, e) 4-6 weight parts magnesium stearate. 7. The oral dosage form of claim 3, further consisting essentially of: a) 0.064-0.0212 w/w % povidone, b) 0.0357 w/w % lactose monohydrate, c) 0.00638 w/w % magnesium stearate, d) 0.021 w/w % propylene glycol alginate, and, e) 0.021 w/w % alginic acid. 8. The oral dosage form of claim 3, further consisting essentially of 640 mg of micronized and non-micronized metaxalone. 9. The oral dosage form of claim 3, wherein the weight ratio of micronized metaxalone to non-micronized metaxalone is 60:40. 10. The oral dosage form of claim 1, consisting essentially of 40-80 wt % micronized metaxalone and 20-60 wt % non-micronized metaxalone, a) wherein 90% of said micronized metaxalone are in the range of 50-500 microns, and, b) wherein 2-10% of said non-micronized metaxalone are retained on a #30 sieve and 25-45% of said non-micronized metaxalone are retained on a #120 sieve. 11. The oral dosage form of claim 3, consisting essentially of 640 weight parts metaxalone and 10-30 weight parts propylene glycol alginate. 12. A tablet oral dosage form made by the following steps consisting essentially of: a) preparing a granulating solution by dissolving povidone in purified water by mixing; b) pre-mixing micronized and non-micronized metaxalone, propylene glycol alginate and alginic acid at a suitable head speed producing a pre-mix blend; c) wet granulating said pre-mix blend while adding said granulating solution to said pre-mix blend producing a wet granulation product; d) drying said wet granulation product to a predetermined moisture content producing a dried granulation product; e) commute milling said dried granulation product producing a milled product; f) mixing magnesium stearate into said milled product; and g) compressing said milled product producing said tablet oral dosage form. 13. The tablet of claim 12, wherein the tablet consists essentially of: a) 640 mg micronized and non-micronized metaxalone, b) 10-30 weight parts propylene glycol alginate, c) 10-30 weight parts alginic acid, and, d) 4-6 weight parts magnesium stearate, e) wherein said metaxalone consists essentially of 40-80 wt % micronized metaxalone and 20-60 wt % non-micronized metaxalone, f) wherein 90% of said micronized metaxalone are in the range of 50-500 microns, and, g) wherein 2-10% of said non-micronized metaxalone are retained on a #30 sieve and 25-45% of said non-micronized metaxalone are retained on a #120 sieve. 14. A solid oral pharmaceutical tablet consisting essentially of 640 mg of metaxalone and one or more pharmaceutically acceptable excipients, wherein: a) the metaxalone consists essentially of from 40 to 80 wt % of a first grade of particles of metaxalone and from 20 to 60 wt % of a second grade of particles of metaxalone; b) 90% of the first grade of particles of metaxalone are smaller than 100 microns when tested according to the Malvern Method; and c) at least 35% of the second grade of particles of metaxalone are retained on a #120 sieve when tested by the Sieve Method. 15. The tablet of claim 14 wherein the first and second grades of metaxalone cause the oral dosage form to be bioequivalent to itself under both fed and fasted conditions in terms of AUC0-inf, wherein said bioequivalence is the 90% confidence interval for a geometric mean test-to-reference area, and whereby peak concentration ratios are within a bioequivalence interval of 0.80-1.25.